Legend Biotech Corporation

NasdaqGS:LEGN Stock Report

Market Cap: US$6.3b

Legend Biotech Future Growth

Future criteria checks 5/6

Legend Biotech is forecast to grow earnings and revenue by 69.6% and 35.6% per annum respectively. EPS is expected to grow by 75.6% per annum. Return on equity is forecast to be 19.3% in 3 years.

Key information

69.6%

Earnings growth rate

75.6%

EPS growth rate

Biotechs earnings growth27.6%
Revenue growth rate35.6%
Future return on equity19.3%
Analyst coverage

Good

Last updated20 Dec 2024

Recent future growth updates

Legend Biotech Corporation (NASDAQ:LEGN) Just Released Its Third-Quarter Earnings: Here's What Analysts Think

Nov 15
Legend Biotech Corporation (NASDAQ:LEGN) Just Released Its Third-Quarter Earnings: Here's What Analysts Think

Recent updates

Legend Biotech: The Story Brightens

Dec 05

Legend Biotech Corporation (NASDAQ:LEGN) Just Released Its Third-Quarter Earnings: Here's What Analysts Think

Nov 15
Legend Biotech Corporation (NASDAQ:LEGN) Just Released Its Third-Quarter Earnings: Here's What Analysts Think

Legend Biotech: Entering Accelerated Growth Phase, Carvykti Positions Company For Valuation Expansion

Sep 18

Optimistic Investors Push Legend Biotech Corporation (NASDAQ:LEGN) Shares Up 26% But Growth Is Lacking

Aug 01
Optimistic Investors Push Legend Biotech Corporation (NASDAQ:LEGN) Shares Up 26% But Growth Is Lacking

Legend Biotech's Promising CAR-T Therapies Face Valuation And Cash Burn Challenges

Jul 30

Rock star Growth Puts Legend Biotech (NASDAQ:LEGN) In A Position To Use Debt

Jul 05
Rock star Growth Puts Legend Biotech (NASDAQ:LEGN) In A Position To Use Debt

Legend Biotech's Carvykti Faces Stiff Challenges Despite Advances

May 14

Some Shareholders Feeling Restless Over Legend Biotech Corporation's (NASDAQ:LEGN) P/S Ratio

May 13
Some Shareholders Feeling Restless Over Legend Biotech Corporation's (NASDAQ:LEGN) P/S Ratio

Legend Biotech: AdCom Documents Shed Light On Carvykti's Problems (Downgrade)

Mar 15

Is Legend Biotech (NASDAQ:LEGN) A Risky Investment?

Mar 06
Is Legend Biotech (NASDAQ:LEGN) A Risky Investment?

Legend Biotech: Solid Traction With Carvykti Rollout

Jan 29

Legend Biotech Corporation's (NASDAQ:LEGN) Share Price Not Quite Adding Up

Jan 16
Legend Biotech Corporation's (NASDAQ:LEGN) Share Price Not Quite Adding Up

Legend Biotech wins approval of Carvykti for multiple myeloma in Japan

Sep 27

Legend Biotech stock slides on proposed ADS offering

Jul 25

Legend Biotech ends Phase 1 trial for lymphoma candidate

Jul 07

Legend Biotech: Carvykti Approval Makes For A Buy Opportunity

Mar 04

Earnings and Revenue Growth Forecasts

NasdaqGS:LEGN - Analysts future estimates and past financials data (USD Millions)
DateRevenueEarningsFree Cash FlowCash from OpAvg. No. Analysts
12/31/20261,54815020421314
12/31/20251,023-144-95-13320
12/31/2024615-278-351-11719
9/30/2024520-348-176-158N/A
6/30/2024456-285-165-143N/A
3/31/2024343-466-264-239N/A
12/31/2023285-518-416-393N/A
9/30/2023233-509-371-347N/A
6/30/2023165-532-378-359N/A
3/31/2023112-517-276-262N/A
12/31/2022117-446-224-201N/A
9/30/2022106-416-237-221N/A
6/30/202296-457-221-194N/A
3/31/2022119-346-293-250N/A
12/31/202169-404-244-198N/A
9/30/202193-356-245-185N/A
6/30/202189-297-259-205N/A
3/31/202180-340-256-204N/A
12/31/202075-266-253-223N/A
9/30/202059-310-300-227N/A
6/30/202064-271-209-143N/A
3/31/202061-165-160-125N/A
1/1/202062-102-110-83N/A
12/31/201849-3287308N/A
12/31/2017249N/A-2N/A

Analyst Future Growth Forecasts

Earnings vs Savings Rate: LEGN is forecast to become profitable over the next 3 years, which is considered faster growth than the savings rate (2.6%).

Earnings vs Market: LEGN is forecast to become profitable over the next 3 years, which is considered above average market growth.

High Growth Earnings: LEGN is expected to become profitable in the next 3 years.

Revenue vs Market: LEGN's revenue (35.6% per year) is forecast to grow faster than the US market (9.1% per year).

High Growth Revenue: LEGN's revenue (35.6% per year) is forecast to grow faster than 20% per year.


Earnings per Share Growth Forecasts


Future Return on Equity

Future ROE: LEGN's Return on Equity is forecast to be low in 3 years time (19.3%).


Discover growth companies

Company Analysis and Financial Data Status

DataLast Updated (UTC time)
Company Analysis2024/12/22 04:32
End of Day Share Price 2024/12/20 00:00
Earnings2024/09/30
Annual Earnings2023/12/31

Data Sources

The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.

PackageDataTimeframeExample US Source *
Company Financials10 years
  • Income statement
  • Cash flow statement
  • Balance sheet
Analyst Consensus Estimates+3 years
  • Forecast financials
  • Analyst price targets
Market Prices30 years
  • Stock prices
  • Dividends, Splits and Actions
Ownership10 years
  • Top shareholders
  • Insider trading
Management10 years
  • Leadership team
  • Board of directors
Key Developments10 years
  • Company announcements

* example for US securities, for non-US equivalent regulatory forms and sources are used.

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.

Analysis Model and Snowflake

Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.

Learn about the world class team who designed and built the Simply Wall St analysis model.

Industry and Sector Metrics

Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on .

Analyst Sources

Legend Biotech Corporation is covered by 27 analysts. 20 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.

AnalystInstitution
Ishan MajumdarBaptista Research
Huidong WangBarclays
Konstantinos BiliourisBMO Capital Markets Equity Research